Literature DB >> 15047194

Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms.

Kayo Sakaguchi1, Mitchell Green, Nicholas Stock, Thomas S Reger, Jasmine Zunic, Christopher King.   

Abstract

Glucuronide conjugation of xenobiotics containing a carboxylic acid moiety represents an important metabolic pathway for these compounds in humans. Several human UDP-glucuronosyltransferases (UGTs) have been shown to catalyze the formation of acyl-glucuronides, including UGT2B7, UGT1A3, and UGT1A9. In this study, recombinant expressed UGT isoforms were investigated with many structurally related carboxylic acid analogues, and the UGT rank order for catalyzing the glucuronidation of carboxylic acids was UGT2B7?UGT1A3 approximately UGT1A9. Despite being a poor substrate with UGT1A3, coumarin-3-carboxylic acid was not a substrate for any other UGT isoform tested in this study, suggesting that it could be a specific substrate for UGT1A3. Interestingly, UGT1A7 and UGT1A10 also react with several carboxylic acid aglycones. Kinetic analysis showed that UGT2B7 exhibits much higher glucuronidation efficiency (Vmax/Km) with ibuprofen, ketoprofen, and others, compared to UGT1A3. These data indicate that UGT2B7 could be the major isoform involved in the glucuronidation of carboxylic acid compounds in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047194     DOI: 10.1016/j.abb.2004.02.004

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

1.  Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver.

Authors:  Yuji Mano; Takashi Usui; Hidetaka Kamimura
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 2.  Pharmacogenomics and histone deacetylase inhibitors.

Authors:  Andrew Kl Goey; Tristan M Sissung; Cody J Peer; William D Figg
Journal:  Pharmacogenomics       Date:  2016-10-21       Impact factor: 2.533

3.  PharmGKB summary: ibuprofen pathways.

Authors:  Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

4.  Nicotine regulates the expression of UDP-glucuronosyltransferase (UGT) in humanized UGT1 mouse brain.

Authors:  Masaya Sakamoto; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Drug Metab Pharmacokinet       Date:  2015-05-07       Impact factor: 3.614

5.  Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition.

Authors:  Tyler S Beyett; Xinmin Gan; Shannon M Reilly; Louise Chang; Andrew V Gomez; Alan R Saltiel; Hollis D Showalter; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2018-08-06       Impact factor: 4.436

Review 6.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 7.  Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.

Authors:  Ping Wang; Xiao-Qian Lin; Wen-Ke Cai; Gui-Li Xu; Meng-Di Zhou; Mei Yang; Gong-Hao He
Journal:  Eur J Clin Pharmacol       Date:  2017-12-14       Impact factor: 2.953

8.  Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

Authors:  Kathleen M Knights; Leanne K Winner; David J Elliot; Kushari Bowalgaha; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

9.  Expression pattern of human ATP-binding cassette transporters in skin.

Authors:  Saya Takenaka; Tomoo Itoh; Ryoichi Fujiwara
Journal:  Pharmacol Res Perspect       Date:  2013-09-08

10.  Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders.

Authors:  Ryoichi Fujiwara; Saya Takenaka; Mitsuhiro Hashimoto; Tomoya Narawa; Tomoo Itoh
Journal:  Sci Rep       Date:  2014-06-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.